


2023 EULAR Recommendations for PsA


Phase 1




Clinical diagnosis of active PsA




Phase 2



Phase 3



Phase 4



*≥4 swollen joints, with or without dactylitis.

1. Some studies suggest that enthesitis may respond to methotrexate, but the level of evidence is low; 2. No glucocorticoids for axial disease; 3. The target is remission or low disease activity (especially with long standing disease) in accordance with the treat-to-target recommendations; 4. Preferred in the presence of relevant skin involvement, however in case of concomitant inflammatory bowel disease or uveitis, a TNF monoclonal antibody or (for IBD) IL-23i or 12/23i or JAKi is recommended; 5. Improvement means at least 50% reduction in disease activity; 6. Arthritis/enthesitis: TNFi or IL-17i or IL-12/23i or IL23p19i; Skin: IL-17i or IL-12/23i or IL-23p19i; Uveitis: anti-TNF monoclonal antibody or IL-12/23i or IL-23p19i or JAKi; Consider using PDE4i in mild disease if bDMARD and JAKi is inappropriate; 7. For JAK-inhibitors, caution is needed for patients aged 65 years or above, current or past long-time smokers, with a history of atherosclerotic cardiovascular disease or other cardiovascular risk factors or with other malignancy risk factors; with known risk factors for venous thromboembolism; 8. Consider tapering in sustained remission; 9. Including abatacept.


bDMARD=Biologic Disease-Modifying Antirheumatic Drugs; csDMARD=Conventional Synthetic Disease-Modifying Antirheumatic Drug; EULAR=European Alliance of Associations for Rheumatology; IBD=Inflammatory Bowel Disease; IL=Interleukin; JAK(i)=Janus Kinase (Inhibitor); NSAID=Non-Steroidal Anti-Inflammatory Drug; PsA=Psoriatic Arthritis; TNF(i)=Tumor Necrosis Factor (Inhibitor).

Gossec L, et al. *Ann Rheum Dis.* 2024;83(6):706-719.



GRAPPA PsA Treatment Recommendations 2021

Consider which domains are involved, patient preference, previous/concomitant therapies; choice therapy should address as many domains as possible



Comorbidities and associated conditions may impact choice of therapy and/or guide monitoring

Treat, periodically re-evaluate treatment goals and modify therapy as required

Strong recommendations shown only; please refer to full guidelines for conditional recommendations.

The order of the products in the boxes is sorted by mechanism of action and does not reflect guidance on relative efficacy or suggested usage.

bDMARD=Biologic DMARD; csDMARD=Conventional Synthetic DMARD; ETN=Etanercept; GRAPPA=Group for Research and Assessment of Psoriasis and Psoriatic Arthritis; IBD=Inflammatory Bowel Disease; JAKi=Janus Kinase Inhibitor; Phototx=Phototherapy; PDE4i=Phosphodiesterase 4 Inhibitor; PsA=Psoriatic Arthritis; TNFi=TNF Inhibitor.

Coates LC, et al. *Nat Rev Rheumatol*. 2022;18(8):465-479.

VV-MED-162198 © Lilly USA, LLC 2024. All rights reserved.

